CPT® Code 86051

Official Description

Aquaporin-4 (neuromyelitis optica [NMO]) antibody; enzyme-linked immunosorbent immunoassay (ELISA)

Common Language Description

The CPT® Code 86051 refers to the testing for Aquaporin-4 (AQP4) antibodies, which are significant markers for neuromyelitis optica (NMO), an autoimmune disorder characterized by inflammation and demyelination within the central nervous system (CNS). NMO primarily impacts the optic nerves and spinal cord, but it can also affect the brain, leading to a range of severe symptoms. These symptoms may include vision loss, limb weakness or paralysis, uncontrollable vomiting or hiccups, painful muscle spasms, and dysfunction of the bladder or bowel. In pediatric cases, the condition can manifest as seizures or even coma. The presence of AQP4 antibodies, also referred to as NMO-IgG, is crucial for distinguishing NMO from multiple sclerosis (MS), as these antibodies are typically found in individuals with NMO but not in those with classical MS. The testing process involves obtaining a venous blood sample, which is then analyzed using the enzyme-linked immunosorbent immunoassay (ELISA) method. This method is capable of detecting minute quantities of the antigen when it is bound to its specific antibody, utilizing a secondary enzyme-labeled antibody to indicate its presence through a chromogenic reaction that results in a visible color change or fluorescence. The results can be assessed qualitatively and semi-quantitatively through colorimetric readings. The AQP4 ELISA test serves as a vital tool for both initial diagnosis and ongoing monitoring of the disease, and it may be complemented by additional testing methods, such as a cell-based immunofluorescence assay (IFA), for further diagnostic clarity.

1. Indications

The Aquaporin-4 (NMO) antibody test is indicated for the following conditions:

Neuromyelitis Optica (NMO) This test is primarily performed to diagnose NMO, an autoimmune disorder that leads to inflammation and demyelination in the central nervous system.
Differentiation from Multiple Sclerosis (MS) The presence of AQP4 antibodies helps differentiate NMO from multiple sclerosis, which is critical for determining the appropriate treatment plan.
Monitoring Disease Activity The AQP4 antibody test is also used for ongoing monitoring of patients diagnosed with NMO to assess disease progression or response to treatment.
Evaluation of Symptoms It may be indicated in patients presenting with symptoms such as vision loss, limb weakness, or other neurological deficits that could suggest NMO.

2. Procedure

The procedure for testing Aquaporin-4 antibodies involves several key steps:

Step 1: Sample Collection A venous blood sample is collected from the patient. This sample serves as the basis for the subsequent testing.
Step 2: Serum Preparation The collected blood sample is processed to separate the serum, which contains the antibodies of interest. This step is crucial for ensuring that the test results are accurate and reliable.
Step 3: Enzyme-Linked Immunosorbent Assay (ELISA) The serum is then subjected to the enzyme-linked immunosorbent immunoassay (ELISA) method. In this step, the serum is mixed with specific antigens that bind to any AQP4 antibodies present.
Step 4: Detection A secondary enzyme-labeled antibody is added to the mixture. This antibody binds to the AQP4 antibodies, forming a complex that can be detected. A chromogenic reaction occurs, producing a visible color change or fluorescence, indicating the presence of the antibodies.
Step 5: Result Interpretation The results are assessed qualitatively and semi-quantitatively through colorimetric readings, which provide information on the concentration of AQP4 antibodies in the serum.

3. Post-Procedure

After the procedure, the patient may experience no significant side effects, as the blood draw is a routine procedure. The results of the AQP4 antibody test are typically available within a few days, and they are used to inform the diagnosis and management of neuromyelitis optica. It is important for healthcare providers to discuss the results with the patient, including any implications for treatment and the need for further testing, such as a cell-based immunofluorescence assay (IFA) for additional diagnostic support. Ongoing monitoring may be necessary to assess disease progression and treatment efficacy.

Short Descr	AQUAPORIN-4 ANTB ELISA
Medium Descr	AQUAPORIN-4 ANTIBODY ELISA
Long Descr	Aquaporin-4 (neuromyelitis optica [NMO]) antibody; enzyme-linked immunosorbent immunoassay (ELISA)
Status Code	Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days	XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC)	9 - Not Applicable
Multiple Procedures (51)	9 - Concept does not apply.
Bilateral Surgery (50)	9 - Concept does not apply.
Physician Supervisions	09 - Concept does not apply.
Assistant Surgeon (80, 82)	9 - Concept does not apply.
Co-Surgeons (62)	9 - Concept does not apply.
Team Surgery (66)	9 - Concept does not apply.
Diagnostic Imaging Family	99 - Concept Does Not Apply
CLIA Waived (QW)	No
APC Status Indicator	Conditionally packaged laboratory tests
Type of Service (TOS)	5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS)	none
MUE	1

Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number.

Repeat clinical diagnostic laboratory test: in the course of treatment of the patient, it may be necessary to repeat the same laboratory test on the same day to obtain subsequent (multiple) test results. under these circumstances, the laboratory test performed can be identified by its usual procedure number and the addition of modifier 91. note: this modifier may not be used when tests are rerun to confirm initial results; due to testing problems with specimens or equipment; or for any other reason when a normal, one-time, reportable result is all that is required. this modifier may not be used when other code(s) describe a series of test results (eg, glucose tolerance tests, evocative/suppression testing). this modifier may only be used for laboratory test(s) performed more than once on the same day on the same patient.